CN109843378B - 用于治疗肺血管疾病的组合物和方法 - Google Patents

用于治疗肺血管疾病的组合物和方法 Download PDF

Info

Publication number
CN109843378B
CN109843378B CN201780044719.7A CN201780044719A CN109843378B CN 109843378 B CN109843378 B CN 109843378B CN 201780044719 A CN201780044719 A CN 201780044719A CN 109843378 B CN109843378 B CN 109843378B
Authority
CN
China
Prior art keywords
pro
leu
ser
gly
gln
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780044719.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN109843378A (zh
Inventor
S·Y·陈
T·贝尔泰罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
University of Pittsburgh
Original Assignee
Brigham and Womens Hospital Inc
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, University of Pittsburgh filed Critical Brigham and Womens Hospital Inc
Priority to CN202210549523.6A priority Critical patent/CN115192719B/zh
Publication of CN109843378A publication Critical patent/CN109843378A/zh
Application granted granted Critical
Publication of CN109843378B publication Critical patent/CN109843378B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201780044719.7A 2016-05-26 2017-05-25 用于治疗肺血管疾病的组合物和方法 Active CN109843378B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210549523.6A CN115192719B (zh) 2016-05-26 2017-05-25 用于治疗肺血管疾病的组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341848P 2016-05-26 2016-05-26
US62/341,848 2016-05-26
PCT/US2017/034420 WO2017205595A1 (en) 2016-05-26 2017-05-25 Compositions and methods for treating pulmonary vascular disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210549523.6A Division CN115192719B (zh) 2016-05-26 2017-05-25 用于治疗肺血管疾病的组合物和方法

Publications (2)

Publication Number Publication Date
CN109843378A CN109843378A (zh) 2019-06-04
CN109843378B true CN109843378B (zh) 2022-06-10

Family

ID=60412630

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210549523.6A Active CN115192719B (zh) 2016-05-26 2017-05-25 用于治疗肺血管疾病的组合物和方法
CN201780044719.7A Active CN109843378B (zh) 2016-05-26 2017-05-25 用于治疗肺血管疾病的组合物和方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202210549523.6A Active CN115192719B (zh) 2016-05-26 2017-05-25 用于治疗肺血管疾病的组合物和方法

Country Status (7)

Country Link
US (2) US10925869B2 (enExample)
EP (2) EP3463574B1 (enExample)
JP (2) JP7079937B2 (enExample)
KR (2) KR102434879B1 (enExample)
CN (2) CN115192719B (enExample)
AU (1) AU2017270092B2 (enExample)
WO (1) WO2017205595A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10925869B2 (en) 2016-05-26 2021-02-23 University of Pittsburgh—of the Commonwealth System of Higher Education Compositions and methods for treating pulmonary vascular disease
US20200276125A1 (en) * 2017-11-22 2020-09-03 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for administering a yap1/wwrt1 inhibiting composition and a gls1 inhibiting composition
JP7156856B2 (ja) * 2018-08-21 2022-10-19 国立大学法人富山大学 抗肥満剤
EP3690109B1 (en) 2019-02-01 2021-05-05 LG Electronics Inc. Laundry treating apparatus
EP3690110B1 (en) 2019-02-01 2021-06-02 LG Electronics Inc. Laundry treating apparatus
EP3690108B1 (en) 2019-02-01 2021-05-12 LG Electronics Inc. Laundry treating apparatus
US20220233535A1 (en) * 2019-05-05 2022-07-28 Georgetown University Use of inhibitors of yap/taz for the treatment of cancer
US20220233542A1 (en) * 2019-06-05 2022-07-28 University Of Georgia Research Foundation Compositions and methods for preventing or treating human immunodeficiency virus associated pulmonary arterial hypertension
JP7514508B2 (ja) * 2020-05-19 2024-07-11 国立大学法人鳥取大学 胆道がん治療薬
US20240082158A1 (en) * 2020-05-21 2024-03-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for administering a yap1/wwrt1 inhibiting composition and a gls1 inhibiting composition
CN116421591A (zh) * 2023-05-10 2023-07-14 哈尔滨医科大学大庆分校 Ldha抑制剂在制备治疗肺动脉高压的药物中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5798345A (en) 1990-09-21 1998-08-25 Bone Care International, Inc. Method of inhibiting the hyperproliferation of malignant cells
US5707608A (en) 1995-08-02 1998-01-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
US5756541A (en) 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
WO2009102707A2 (en) * 2008-02-11 2009-08-20 Auspex Pharmaceuticals, Inc. Substituted oxazaphosphorines
EP2279267A4 (en) * 2008-03-27 2012-01-18 Vascular Biosciences Inc METHOD FOR IDENTIFYING NEW THERAPY CANDIDATES ON GENE EXPRESSION ANALYSIS IN DISEASES RELATED TO VACCINES
KR100963435B1 (ko) 2008-06-19 2010-06-17 한국과학기술연구원 서방형 약물전달 및 조직재생용 덮인 다공성 생분해성고분자 미립구의 제조 방법
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US20150258082A1 (en) 2014-03-14 2015-09-17 Francesco Parlati Combination therapy with glutaminase inhibitors
US20170226507A1 (en) 2014-05-05 2017-08-10 The Brigham And Women's Hospital, Inc. Coordinate control of pathogenic signaling by the mir-130/301 family in pulmonary hypertension and fibroproliferative diseases
US20160058759A1 (en) 2014-07-03 2016-03-03 Board Of Regents, The University Of Texas System Glutaminase inhibitor therapy
US10660861B2 (en) 2014-07-09 2020-05-26 The Johns Hopkins University Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy
WO2016019368A1 (en) * 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
WO2016054388A1 (en) 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
WO2016077632A2 (en) 2014-11-13 2016-05-19 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
AU2016219161A1 (en) 2015-02-12 2017-08-31 The Johns Hopkins University Inhibition of Yap for breaking tumor immune tolerance
US20180311353A1 (en) 2015-07-02 2018-11-01 Children's Medical Center Corporation Triplet-triplet annihilation-based upconversion
WO2017095751A1 (en) 2015-12-02 2017-06-08 Partikula Llc Compositions and methods for modulating cancer cell metabolism
US10925869B2 (en) * 2016-05-26 2021-02-23 University of Pittsburgh—of the Commonwealth System of Higher Education Compositions and methods for treating pulmonary vascular disease
US20200276125A1 (en) * 2017-11-22 2020-09-03 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for administering a yap1/wwrt1 inhibiting composition and a gls1 inhibiting composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bertero.Matrix remodeling promotes pulmonary hypertension through feedback mechanoactivation of the YAP/TAZ-miR-130/301 circuit.《Cell Rep》.2015,第13卷(第5期),第1016-1032页. *
Matrix remodeling promotes pulmonary hypertension through feedback mechanoactivation of the YAP/TAZ-miR-130/301 circuit;Bertero;《Cell Rep》;20151103;第13卷(第5期);第1016-1032页 *
The Hippo pathway mediates inhibition of vascular smooth muscle cell proliferation by cAMP;Kimura等;《Journal of Molecular and Cellular Cardiology》;20151125;第90卷;第1-10页 *

Also Published As

Publication number Publication date
US10925869B2 (en) 2021-02-23
JP2019519533A (ja) 2019-07-11
EP3463574A1 (en) 2019-04-10
US20210154187A1 (en) 2021-05-27
EP3970720A1 (en) 2022-03-23
WO2017205595A1 (en) 2017-11-30
AU2017270092A1 (en) 2018-12-06
JP2022119825A (ja) 2022-08-17
EP3463574B1 (en) 2021-11-03
EP3463574A4 (en) 2020-07-29
CN109843378A (zh) 2019-06-04
CN115192719B (zh) 2024-03-01
KR20220120711A (ko) 2022-08-30
EP3970720B1 (en) 2023-07-05
CA3025401A1 (en) 2017-11-30
AU2017270092B2 (en) 2022-04-14
JP7079937B2 (ja) 2022-06-03
JP7411967B2 (ja) 2024-01-12
KR102434879B1 (ko) 2022-08-22
US11672795B2 (en) 2023-06-13
KR20190013926A (ko) 2019-02-11
US20190298710A1 (en) 2019-10-03
CN115192719A (zh) 2022-10-18

Similar Documents

Publication Publication Date Title
CN109843378B (zh) 用于治疗肺血管疾病的组合物和方法
Yang et al. The ER-localized Ca2+-binding protein calreticulin couples ER stress to autophagy by associating with microtubule-associated protein 1A/1B light chain 3
RU2736499C1 (ru) Специфические ингибиторы гексокиназы-2 для применения при остром повреждении центральной нервной системы
US20130288981A1 (en) Targeting senescent cells and cancer cells by interference with jnk and/or foxo4
EP2699319A1 (en) Niclosamide for the treatment of cancer metastasis
WO2019037222A1 (zh) Gpr31抑制剂在制药中的应用
WO2017208174A2 (en) Methods of treating disease with pfkfb3 inhibitors
AU2017281980B2 (en) Wnt inhibitors for use in the treatment of fibrosis
Chen et al. Lercanidipine attenuates angiotensin II-induced cardiomyocyte hypertrophy by blocking calcineurin-NFAT3 and CaMKII-HDAC4 signaling
KR20210069626A (ko) Etv6 또는 foxo1의 발현을 조절하는 중간체 비-코딩 rna 조절인자를 포함하는 조성물 및 이의 용도
CN112839708A (zh) 用于减少或治疗纤维化的组合物和方法
EP4093426A1 (en) Modulating lymphatic vessels in neurological disease
Wei et al. Cyclic guanosine monophosphate-adenosine monophosphate synthetase/stimulator of interferon genes signaling aggravated corneal allograft rejection through neutrophil extracellular traps
US20230365626A1 (en) Alloferon Peptide and Method Using the Same
AU2022203624A1 (en) Compositions and methods for treating pulmonary vascular disease
CA3025401C (en) Compositions and methods for treating pulmonary vascular disease
Zhao et al. GDF11 alleviates cardiac ischemia/reperfusion injury by suppressing the mtDNA damage-inflammatory response axis
HK40006997B (en) Compositions and methods for treating pulmonary vascular disease
Situ Uncovering the Role of Connexin-43 in Blood Brain Barrier Dysfunction in Cerebral Amyloid Angiopathy
US20090221610A1 (en) Compositions and Methods for Treating Cognitive Disorders
Zhang et al. Inhibition of ARC promoting the apoptosis of rat pulmonary arterial smooth muscle cells after serum deprivation in vitro
Vigil The Role of Aconitate Decarboxylase 1 in Inflammation and Disease
石丸晃成 Deferasirox Targeting Ferroptosis Synergistically Ameliorates Myocardial Ischemia Reperfusion Injury in Conjunction With Cyclosporine A
Peters-Golden et al. Kruppel-like factor 4 as a therapeutically tractable brake on lung fibroblast activation which promotes resolution of pulmonary fibrosis
KR20230034167A (ko) Kai1 폴리펩타이드를 포함하는 간 섬유화 억제용 약학 조성물 및 이의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant